- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Thyroid hormone receptor.
Displaying page 1 of 1.
EudraCT Number: 2005-004451-35 | Sponsor Protocol Number: MRTSH01505 | Start Date*: 2007-03-13 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi... | |||||||||||||
Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000209-35 | Sponsor Protocol Number: 7805 | Start Date*: 2016-08-24 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism | ||
Medical condition: Graves' hyperthyroidism | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001707-11 | Sponsor Protocol Number: M06HER | Start Date*: 2007-06-07 |
Sponsor Name:NKI-AvL | ||
Full Title: Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated ca... | ||
Medical condition: WHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic ≥ 140 mmHg diastolic ≥ 90 mmHg is acceptable at randomization. LVEF 50% assessed b... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000320-14 | Sponsor Protocol Number: D6997L00002 (9238SW0001) | Start Date*: 2006-03-29 |
Sponsor Name:AstraZeneca oy | ||
Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ... | ||
Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005200-19 | Sponsor Protocol Number: I-CONIC | Start Date*: 2022-05-09 |
Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken | ||
Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC" | ||
Medical condition: Early Triple Negative Breast Cancer planned for surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002790-22 | Sponsor Protocol Number: ML39921 | Start Date*: 2019-04-11 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | ||||||||||||||||||
Full Title: Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in pat... | ||||||||||||||||||
Medical condition: Active moderate-severe Graves' Orbitopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000797-30 | Sponsor Protocol Number: SPI-IIT-002 | Start Date*: 2013-10-08 | |||||||||||||||||||||
Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital | |||||||||||||||||||||||
Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation | |||||||||||||||||||||||
Medical condition: Paroxysmal and persistent atrial fibrillation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001295-36 | Sponsor Protocol Number: SRM105106 | Start Date*: 2007-08-22 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 ad... | ||
Medical condition: Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002017-22 | Sponsor Protocol Number: 63723283LUC1001 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with A... | |||||||||||||
Medical condition: Advanced Stage Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002278-30 | Sponsor Protocol Number: APH-19 | Start Date*: 2020-08-12 | |||||||||||
Sponsor Name:Amryt Pharmaceuticals DAC | |||||||||||||
Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002449-19 | Sponsor Protocol Number: LBH589C2204 | Start Date*: 2008-05-08 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with... | |||||||||||||
Medical condition: metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000931-15 | Sponsor Protocol Number: ICR-CTSU/2016/10060 | Start Date*: 2018-07-02 |
Sponsor Name:Institute of Cancer Research | ||
Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer. | ||
Medical condition: Metastatic Castration Resistant Prostate Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019497-32 | Sponsor Protocol Number: PGL09-027 | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:PregLem S.A. | |||||||||||||
Full Title: A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatme... | |||||||||||||
Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly as... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) AT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000899-23 | Sponsor Protocol Number: CORT125134-451 | Start Date*: 2016-08-16 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003096-35 | Sponsor Protocol Number: CORT125134-455 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | |||||||||||||
Medical condition: Endogenous Cushing syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BG (Completed) AT (Completed) PL (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002507-34 | Sponsor Protocol Number: GSN000200 | Start Date*: 2014-02-20 | |||||||||||||||||||||
Sponsor Name:Genkyotex Innovation SAS | |||||||||||||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria | |||||||||||||||||||||||
Medical condition: Patients with type 2 diabetes and albuminuria. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
